New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
India now has 648 medical colleges in 2022 with a whopping 96% increase in the number of Government Medical Colleges (GMC) alone and a 42% increase in the private sector, since 2014
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
The company is focussed on increasing the capacity utilizations while controlling costs
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
Subscribe To Our Newsletter & Stay Updated
